Steven O'Day M.D.
Medical Oncology

Steven J. O’Day

M.D.

Professor of Medical Oncology
Director of Immuno-Oncology
Director of Clinical Research
Co-Director of Melanoma and Cutaneous Oncology Research Program

Dr. Steven J. O’Day, is the Professor of Medical Oncology, Director of Immuno-Oncology, Director of Clinical Research at the John Wayne Cancer Institute at Providence Saint John’s Health Center. Previously Dr. O’Day was Chief of Research and Director of the Melanoma Program at The Angeles Clinic and Research Institute in Los Angeles.

Dr. O’Day’s medical training was at Johns Hopkins in Baltimore and the Dana Farber Cancer Institute in Boston. In 1994 Dr. O’Day came to Los Angeles and founded the Medical Oncology Division of The John Wayne Cancer Institute in partnership with the world-class Surgical Oncology faculty and melanoma experts of The John Wayne Cancer Institute. More recently, he was a founding member of The Angeles Clinic and Research Institute in Santa Monica, California.

Dr. O’Day is recognized as one of the preeminent melanoma specialists in the world, and combines expert clinical care with teaching and leading clinical research. He lectures extensively, both nationally and internationally. He has been at the forefront of new drug development in melanoma over the last two decades. Dr. O’Day played a leadership role in the development of the breakthrough immune checkpoint inhibitor ipilimumab as well as the anti-PD1 antibodies pembrolizamab and nivolumab. In addition, he has participated in the development of the MAPK inhibitors vemurafinib, dabrafinib and trametinib.

Dr. O’Day has been a principal investigator on over 100 clinical trials including several large, international Phase III trials. He has published more than 200 manuscripts, abstracts and reviews in prestigious journals such as The New England Journal of Medicine (NEJM), Journal of Clinical Oncology (JCO), Blood, Journal of American Medical Association (JAMA), Cancer, Lancet Oncology and the Journal of the National Cancer Institute.

Dr. O’Day has served on the ASCO Education Committee for melanoma. In addition, he has served on the ASCO International Development and Education Award (IDEA) Working Group where he was a mentor for an IDEA grant recipient as well as an IDEA grant reviewer. Dr. O’Day recently completed a three-year term on the prestigious ASCO Cancer Communications Committee where he moderated ASCO press conferences most notably the ASCO 2014 Immuno-Oncology Press Conference.